---
title: "Fresenius Q2 FY26 core EPS climbs 14% to €0.83; revenue rises 6% to €5.86 billion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294864749.md"
description: "Fresenius reported a 6% organic revenue increase to €5.86 billion and a 14% rise in Q2 FY26 core EPS to €0.83, driven by strong performance at Kabi and Helios. Consequently, the company upgraded its full-year core EPS growth guidance to 10%-15% from 5%-10%. EBIT before special items also grew 10% to €719 million, with margins widening to 12.3%."
datetime: "2026-08-04T20:14:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294864749.md)
  - [en](https://longbridge.com/en/news/294864749.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294864749.md)
generator: "portal-rs"
---

# Fresenius Q2 FY26 core EPS climbs 14% to €0.83; revenue rises 6% to €5.86 billion

-   Fresenius lifted FY2026 core EPS growth guidance to 10%-15% from 5%-10%, citing strong operating performance at Kabi and Helios. \* Q2 2026 revenue rose 6% organically to EUR 5.86 billion. \* Q2 EBIT before special items climbed 10% to EUR 719 million; EBIT margin widened 0.6 percentage point to 12.3%. \* Q2 core EPS before special items rose 14% to EUR 0.83; improved net interest income supported earnings development. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief via EQS News (Ref. ID: adhoc\_2377334\_en) on August 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [FSNUY.US](https://longbridge.com/en/quote/FSNUY.US.md)
- [FRE.DE](https://longbridge.com/en/quote/FRE.DE.md)

## Related News & Research

- [Fresenius Kabi launches generic sugammadex prefilled syringe in US](https://longbridge.com/en/news/297958888.md)
- [Fresenius Kabi Launches Generic Sugammadex in Simplist® Ready‑to‑Administer Prefilled Syringe in the U.S. | FSNUY Stock News](https://longbridge.com/en/news/297960064.md)
- [Fortum guides 2026 Nordic outright generation 80% hedged at EUR 40/MWh](https://longbridge.com/en/news/297915001.md)
- [FRE: Q2 2026 delivered double-digit earnings growth and upgraded guidance on strong segment performance](https://longbridge.com/en/news/294871343.md)
- [Citigroup announces Q3 2026 distribution of R$ 0.39 per unit, payable Sept. 3](https://longbridge.com/en/news/297699755.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**